Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M. & Veiseh, O. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug Discov. 21, 655–675 (2022).
Eckman, N., Nejatfard, A., Cavet, R., Grosskopf, A. K. & Appel, E. A. Biomaterials to enhance adoptive cell therapy. Nat. Rev. Bioeng. 2, 408–424 (2024).
Hotta, A., Schrepfer, S. & Nagy, A. Genetically engineered hypoimmunogenic cell therapy. Nat. Rev. Bioeng. 2, 960–979 (2024).
Deuse, T. & Schrepfer, S. Progress and challenges in developing allogeneic cell therapies. Cell Stem Cell 32, 513–528 (2025).
Viswanathan, S. & Galipeau, J. Hallmarks of MSCs: key quality attributes for pharmacology and clinical use. Cell Stem Cell 32, 878–894 (2025).
Cerneckis, J., Cai, H. & Shi, Y. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Signal Transduct. Target. Ther. 9, 112 (2024).
Skidmore, S. & Barker, R. A. Challenges in the clinical advancement of cell therapies for Parkinson’s disease. Nat. Biomed. Eng. 7, 370–386 (2023).
Svendsen, S. P. & Svendsen, C. N. Cell therapy for neurological disorders. Nat. Med. 30, 2756–2770 (2024).
Levy, O. et al. Shattering barriers toward clinically meaningful MSC therapies. Sci. Adv. 6, eaba6884 (2020).
Martin, I., Galipeau, J., Kessler, C., Le Blanc, K. & Dazzi, F. Challenges for mesenchymal stromal cell therapies. Sci. Transl. Med. 11, eaat2189 (2019).
Noronha Cássia de, N. et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res. Ther. 10, 131 (2019).
Boyt, D. T., Boland, L. K., Burand, A. J., Brown, A. J. & Ankrum, J. A. Dose and duration of interferon γ pre-licensing interact with donor characteristics to influence the expression and function of indoleamine-2,3-dioxygenase in mesenchymal stromal cells. J. R. Soc. Interface 17, 20190815 (2020).
Shan, Y. et al. Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges. Signal Transduct. Target. Ther. 9, 242 (2024).
Herrmann, I. K., Wood, M. J. A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748–759 (2021).
Manno, M., Bongiovanni, A., Margolis, L., Bergese, P. & Arosio, P. The physico-chemical landscape of extracellular vesicles. Nat. Rev. Bioeng. 3, 68–82 (2025).
Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the ‘biological missile’ for targeted cancer therapy. Signal Transduct. Target. Ther. 7, 93 (2022).
Ebrahimi, S. B. & Samanta, D. Engineering protein-based therapeutics through structural and chemical design. Nat. Commun. 14, 2411 (2023).
Xu, G. et al. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies. Signal Transduct. Target. Ther. 10, 255 (2025).
Huang, K. et al. An off-the-shelf artificial cardiac patch improves cardiac repair after myocardial infarction in rats and pigs. Sci. Transl. Med. 12, eaat9683 (2020).
Tang, J. et al. Therapeutic microparticles functionalized with biomimetic cardiac stem cell membranes and secretome. Nat. Commun. 8, 13724 (2017).
Luo, L. et al. Fabrication of synthetic mesenchymal stem cells for the treatment of acute myocardial infarction in mice. Circ. Res. 120, 1768–1775 (2017).
Bao, H. et al. Exosome-loaded degradable polymeric microcapsules for the treatment of vitreoretinal diseases. Nat. Biomed. Eng. 8, 1436–1452 (2024).
Wagoner, Z. W. & Zhao, W. Therapeutic implications of transplanted-cell death. Nat. Biomed. Eng. 5, 379–384 (2021).
Giacomini, C., Granéli, C., Hicks, R. & Dazzi, F. The critical role of apoptosis in mesenchymal stromal cell therapeutics and implications in homeostasis and normal tissue repair. Cell. Mol. Immunol. 20, 570–582 (2023).
Crunkhorn, S. Promoting efferocytosis heals diabetic wounds. Nat. Rev. Drug Discov. 21, 491 (2022).
Maschalidi, S. et al. Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes. Nature 606, 776–784 (2022).
Chen, M. et al. Potentiating cancer vaccination by adjuvant-loaded cryo-shocked tumor cells. Biomaterials 302, 122319 (2023).
Ci, T. et al. Cryo-shocked cancer cells for targeted drug delivery and vaccination. Sci. Adv. 6, eabc3013 (2020).
Wu, L. et al. Camouflaging attenuated Salmonella by cryo-shocked macrophages for tumor-targeted therapy. Signal Transduct. Target. Ther. 9, 14 (2024).
Guo, J. et al. Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns. Nat. Biomed. Eng. 6, 19–31 (2022).
He, X. et al. Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine. Signal Transduct. Target. Ther. 6, 270 (2021).
van Heerden, P. V. et al. Apoptotic cells for therapeutic use in cytokine storm associated with sepsis—a phase Ib clinical trial. Front. Immunol. 12, 718191 (2021).
Liu, F. et al. Cryo-shocked tumor cells deliver CRISPR–Cas9 for lung cancer regression by synthetic lethality. Sci. Adv. 10, eadk8264 (2024).
Bigham, A. et al. Advances in tannic acid-incorporated biomaterials: infection treatment, regenerative medicine, cancer therapy, and biosensing. Chem. Eng. J. 432, 134146 (2022).
Lee, H. et al. A decade of advances in single-cell nanocoating for mammalian cells. Adv. Healthc. Mater. 10, 2100347 (2021).
Barra, J. M. et al. Localized cytotoxic T cell-associated antigen 4 and antioxidant islet encapsulation alters macrophage signaling and induces regulatory and anergic T cells to enhance allograft survival. Am. J. Transplant. 23, 498–511 (2023).
Luk, F. et al. Inactivated mesenchymal stem cells maintain immunomodulatory capacity. Stem Cells Dev. 25, 1342–1354 (2016).
Lim, J.-Y. et al. The therapeutic efficacy of mesenchymal stromal cells on experimental colitis was improved by the IFN-γ and poly(I:C) priming through promoting the expression of indoleamine 2,3-dioxygenase. Stem Cell Res. Ther. 12, 37 (2021).
García, J. R. et al. IFN-γ-tethered hydrogels enhance mesenchymal stem cell-based immunomodulation and promote tissue repair. Biomaterials 220, 119403 (2019).
Vieujean, S. et al. Understanding the therapeutic toolkit for inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 22, 371–394 (2025).
Langer, V. et al. IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption. J. Clin. Invest. 129, 4691–4707 (2019).
Park, H. Y. et al. Priming mesenchymal stem/stromal cells with a combination of a low dose of IFN-γ and bortezomib results in potent suppression of pathogenic Th17 immunity through the IDO1–AHR axis. Stem Cells 41, 64–76 (2023).
Yang, R. et al. IFN-γ promoted exosomes from mesenchymal stem cells to attenuate colitis via miR-125a and miR-125b. Cell Death Dis. 11, 603 (2020).
Wang, D., Chen, W., Cao, J., Si, L. & Chen, Z. Establishment and evaluation of a mouse model of experimental ulcerative colitis induced by the gavage administration of dextran sulfate sodium. Biomedicines 12, 1764 (2024).
Pittenger, M. F. et al. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regen. Med. 4, 22 (2019).
Han, Y. et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Sig. Transduct. Target. Ther. 7, 92 (2022).
Hoang, D. M. et al. Stem cell-based therapy for human diseases. Sig. Transduct. Target Ther. 7, 272 (2022).
Li, Y. et al. Primed 3D injectable microniches enabling low-dosage cell therapy for critical limb ischemia. Proc. Natl Acad. Sci. USA 111, 13511–13516 (2014).
Han, J., Luo, L., Marcelina, O., Kasim, V. & Wu, S. Therapeutic angiogenesis-based strategy for peripheral artery disease. Theranostics 12, 5015–5033 (2022).
Golledge, J. Pathology, progression, and emerging treatments of peripheral artery disease–related limb ischemia. Clin. Ther. 45, 1077–1086 (2023).
Sharma, S. et al. Protocol for modeling blood flow recovery and angiogenesis in response to hindlimb ischemia. STAR Protoc. 6, 103783 (2025).
Evans, W. S., Pena, G. S., Gelman, B., Kuzmiak-Glancy, S. & Prior, S. J. Unilateral hindlimb ischaemia-induced systemic inflammation is associated with non-ischaemic skeletal muscle inflammation. Exp. Physiol. 109, 1604–1613 (2024).
Dhanjal, D. S. et al. Concepts of advanced therapeutic delivery systems for the management of remodeling and inflammation in airway diseases. Future Med. Chem. 14, 271–288 (2022).
Ita, K. in Drug Delivery 43–70 (Academic Press, 2025).
Lee, W. T. et al. Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis. Bioact. Mater 33, 262–278 (2024).
Mok, Z. H. The effect of particle size on drug bioavailability in various parts of the body. Pharm. Sci. Adv. 2, 100031 (2024).
Salthouse, D., Novakovic, K., Hilkens, C. M. U. & Ferreira, A. M. Interplay between biomaterials and the immune system: challenges and opportunities in regenerative medicine. Acta Biomater. 155, 1–18 (2023).
Lee, Y., Jeong, M., Park, J., Jung, H. & Lee, H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 55, 2085–2096 (2023).
Behzadi, S. et al. Cellular uptake of nanoparticles: journey inside the cell. Chem. Soc. Rev. 46, 4218–4244 (2017).
Lambrecht, B. N., Ahmed, E. & Hammad, H. The immunology of asthma. Nat. Immunol. 26, 1233–1245 (2025).
Schu, S. et al. Immunogenicity of allogeneic mesenchymal stem cells. J. Cell. Mol. Med. 16, 2094–2103 (2012).
Rasmusson, I., Le Blanc, K., Sundberg, B. & Ringdén, O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand. J. Immunol. 65, 336–343 (2007).
Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586–1600 (2022).
Lozano Navarro, L. V. et al. Mesenchymal stem cells for critical limb ischemia: their function, mechanism, and therapeutic potential. Stem Cell Res. Ther. 13, 345 (2022).
Galleu, A. et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci. Transl. Med. 9, eaam7828 (2017).
Pang, S. H. M. et al. Mesenchymal stromal cell apoptosis is required for their therapeutic function. Nat. Commun. 12, 6495 (2021).
Preda, M. B. et al. Short lifespan of syngeneic transplanted MSC is a consequence of in vivo apoptosis and immune cell recruitment in mice. Cell Death Dis. 12, 566 (2021).
Dave, M. et al. MSCs mediate long-term efficacy in a Crohn’s disease model by sustained anti-inflammatory macrophage programming via efferocytosis. npj Regen. Med. 9, 6 (2024).
Karbian, N. et al. Apoptotic cell therapy for cytokine storm associated with acute severe sepsis. Cell Death Dis. 11, 535 (2020).
Weiss, A. R. R. et al. Differential effects of heat-inactivated, secretome-deficient MSC and metabolically active MSC in sepsis and allogenic heart transplantation. Stem Cells 38, 797–807 (2020).
Wu, Q. et al. Inhibition of tumor metastasis by liquid-nitrogen-shocked tumor cells with oncolytic viruses infection. Adv. Mater. 35, e2212210 (2023).
Shi, X. et al. Combination of cryo-shocked M1 macrophages and lonidamine nanodrugs enables potent chemo-immunotherapy. Adv. Funct. Mater. 34, 2310364 (2024).
Gao, Q. et al. Autologous cryo-shocked neutrophils enable targeted therapy of sepsis via broad-spectrum neutralization of pro-inflammatory cytokines and endotoxins. Front. Chem. 12, 1359946 (2024).
Quan, X. et al. Cryo-shocked platelet coupled with ROS-responsive nanomedicine for targeted treatment of thromboembolic disease. ACS Nano 17, 6519–6533 (2023).
Shin, M. et al. Targeting protein and peptide therapeutics to the heart via tannic acid modification. Nat. Biomed. Eng. 2, 304–317 (2018).
He, Z. et al. Sustained release of exendin-4 from tannic acid/Fe (III) nanoparticles prolongs blood glycemic control in a mouse model of type II diabetes. J. Control. Release 301, 119–128 (2019).
Shin, M. et al. DNA/tannic acid hybrid gel exhibiting biodegradability, extensibility, tissue adhesiveness, and hemostatic ability. Adv. Funct. Mater. 25, 1270–1278 (2015).
Utatsu, K., Motoyama, K., Nakamura, T., Onodera, R. & Higashi, T. Tannic acid-based sustained-release system for protein drugs. Int. J. Pharm. 643, 123229 (2023).
Wang, H. et al. Genetically engineered and enucleated human mesenchymal stromal cells for the targeted delivery of therapeutics to diseased tissue. Nat. Biomed. Eng. 6, 882–897 (2022).
Nascimento do, J. M. et al. Evaluation of the influence of temperature on the protein–tannic acid complex. Int. J. Biol. Macromol. 182, 2056–2065 (2021).
Chen, C., Yang, H., Yang, X. & Ma, Q. Tannic acid: a crosslinker leading to versatile functional polymeric networks: a review. RSC Adv. 12, 7689–7711 (2022).
Leduc, A., Xu, Y., Shipkovenska, G., Dou, Z. & Slavov, N. Limiting the impact of protein leakage in single-cell proteomics. Nat. Commun. 16, 4169 (2025).
Pack, C.-G. Application of quantitative cell imaging using label-free optical diffraction tomography. Biophys. Physicobiology 18, 244–253 (2021).
Suzuki, M., Shindo, Y., Yamanaka, R. & Oka, K. Live imaging of apoptotic signaling flow using tunable combinatorial FRET-based bioprobes for cell population analysis of caspase cascades. Sci. Rep. 12, 21160 (2022).
Huang, S. et al. Mesenchymal stem/stromal cells in asthma therapy: mechanisms and strategies for enhancement. Cell Transplant. 32, 09636897231180128 (2023).
Choi, J. Y., Hur, J., Jeon, S., Jung, C. K. & Rhee, C. K. Effects of human adipose tissue- and bone marrow-derived mesenchymal stem cells on airway inflammation and remodeling in a murine model of chronic asthma. Sci. Rep. 12, 12032 (2022).
Janowski, M. et al. Cell size and velocity of injection are major determinants of the safety of intracarotid stem cell transplantation. J. Cereb. Blood Flow Metab. 33, 921–927 (2013).
Nguyen, T. T. et al. Engineering of hybrid spheroids of mesenchymal stem cells and drug depots for immunomodulating effect in islet xenotransplantation. Sci. Adv. 8, eabn8614 (2022).
Gonzalez-Pujana, A. et al. Mesenchymal stromal cells encapsulated in licensing hydrogels exert delocalized systemic protection against ulcerative colitis via subcutaneous xenotransplantation. Eur. J. Pharm. Biopharm. 172, 31–40 (2022).
Ishiuchi, N. et al. Hypoxia-preconditioned mesenchymal stem cells prevent renal fibrosis and inflammation in ischemia-reperfusion rats. Stem Cell Res. Ther. 11, 130 (2020).
Carew, J. S. et al. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 107, 222–231 (2006).
Elman, J. S. et al. Pharmacokinetics of natural and engineered secreted factors delivered by mesenchymal stromal cells. PLoS ONE 9, e89882 (2014).
Ankrum, J. A. et al. Engineering cells with intracellular agent-loaded microparticles to control cell phenotype. Nat. Protoc. 9, 233–245 (2014).
Nguyen, T. T. et al. Engineering ‘cell-particle hybrids’ of pancreatic islets and bioadhesive FK506-loaded polymeric microspheres for local immunomodulation in xenogeneic islet transplantation. Biomaterials 221, 119415 (2019).
Martin, J. A. & Wang, Z. Next-generation transcriptome assembly. Nat. Rev. Genet. 12, 671–682 (2011).
Jin, S. et al. Conditioned medium derived from FGF-2-modified GMSCs enhances migration and angiogenesis of human umbilical vein endothelial cells. Stem Cell Res. Ther. 11, 68 (2020).
Kim, Y.-J. et al. Increasing angiogenic efficacy of conditioned medium using light stimulation of human adipose-derived stem cells. Commun. Biol. 5, 957 (2022).
Kong, L. et al. Conditioned media from endothelial progenitor cells cultured in simulated microgravity promote angiogenesis and bone fracture healing. Stem Cell Res. Ther. 12, 47 (2021).
Ramesh, A., Kumar, S., Nguyen, A., Brouillard, A. & Kulkarni, A. Lipid-based phagocytosis nanoenhancer for macrophage immunotherapy. Nanoscale 12, 1875–1885 (2020).
Wang, B. et al. mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2. Stem Cell Res. Ther. 8, 292 (2017).
Lee, J. B. et al. Microchannel network hydrogel induced ischemic blood perfusion connection. Nat. Commun. 11, 615 (2020).
Wang, L., Chen, Z., Li, Y., Yang, J. & Li, Y. Optical coherence tomography angiography for noninvasive evaluation of angiogenesis in a limb ischemia mouse model. Sci. Rep. 9, 5980 (2019).